Hanall Biopharma Co.,Ltd (009420.KS)
KRW 27800.0
(-0.18%)
KRW 27800.0
(-0.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -32.43 Billion KRW | -108.83% |
| 2022 | -15.53 Billion KRW | -35.53% |
| 2021 | -11.45 Billion KRW | -214.04% |
| 2020 | -3.64 Billion KRW | 34.28% |
| 2019 | -5.55 Billion KRW | 75.52% |
| 2018 | -22.68 Billion KRW | 45.89% |
| 2017 | -41.92 Billion KRW | -341.33% |
| 2016 | -9.49 Billion KRW | -2.28% |
| 2015 | -9.28 Billion KRW | -173.53% |
| 2014 | 12.63 Billion KRW | 105.54% |
| 2013 | 6.14 Billion KRW | -35.5% |
| 2012 | 9.52 Billion KRW | -52.74% |
| 2011 | 20.16 Billion KRW | -54.43% |
| 2010 | 44.24 Billion KRW | 24.31% |
| 2009 | 35.59 Billion KRW | 24.5% |
| 2008 | 28.58 Billion KRW | 102.21% |
| 2007 | 14.13 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -16.58 Billion KRW | 42.69% |
| 2024 Q1 | -28.94 Billion KRW | 10.75% |
| 2023 Q3 | -32.68 Billion KRW | -116.4% |
| 2023 Q4 | -32.43 Billion KRW | 0.79% |
| 2023 FY | -32.43 Billion KRW | -108.83% |
| 2023 Q1 | -20.93 Billion KRW | -34.82% |
| 2023 Q2 | -15.1 Billion KRW | 27.86% |
| 2022 FY | -15.53 Billion KRW | -35.53% |
| 2022 Q2 | -15.37 Billion KRW | 20.37% |
| 2022 Q1 | -19.3 Billion KRW | -68.44% |
| 2022 Q4 | -15.53 Billion KRW | 6.77% |
| 2022 Q3 | -16.65 Billion KRW | -8.38% |
| 2021 Q2 | -6.24 Billion KRW | 37.91% |
| 2021 FY | -11.45 Billion KRW | -214.04% |
| 2021 Q1 | -10.06 Billion KRW | -175.72% |
| 2021 Q3 | -11.33 Billion KRW | -81.45% |
| 2021 Q4 | -11.45 Billion KRW | -1.11% |
| 2020 FY | -3.64 Billion KRW | 34.28% |
| 2020 Q4 | -3.64 Billion KRW | 43.2% |
| 2020 Q1 | -8.71 Billion KRW | -56.98% |
| 2020 Q3 | -6.42 Billion KRW | 26.56% |
| 2020 Q2 | -8.74 Billion KRW | -0.38% |
| 2019 Q4 | -5.55 Billion KRW | 73.4% |
| 2019 FY | -5.55 Billion KRW | 75.52% |
| 2019 Q1 | -18.41 Billion KRW | 18.81% |
| 2019 Q2 | -10.34 Billion KRW | 43.83% |
| 2019 Q3 | -20.87 Billion KRW | -101.78% |
| 2018 Q4 | -22.68 Billion KRW | -129.03% |
| 2018 Q1 | -14.54 Billion KRW | 65.31% |
| 2018 FY | -22.68 Billion KRW | 45.89% |
| 2018 Q2 | -10.66 Billion KRW | 26.68% |
| 2018 Q3 | -9.9 Billion KRW | 7.11% |
| 2017 Q2 | -11.29 Billion KRW | 0.02% |
| 2017 FY | -41.92 Billion KRW | -341.33% |
| 2017 Q4 | -41.92 Billion KRW | -195.08% |
| 2017 Q3 | -14.2 Billion KRW | -25.8% |
| 2017 Q1 | -11.29 Billion KRW | -18.91% |
| 2016 Q3 | -4.92 Billion KRW | 27.53% |
| 2016 FY | -9.49 Billion KRW | -2.28% |
| 2016 Q1 | -16.53 Billion KRW | -77.99% |
| 2016 Q2 | -6.79 Billion KRW | 58.9% |
| 2016 Q4 | -9.49 Billion KRW | -92.9% |
| 2015 Q1 | 11.28 Billion KRW | -10.62% |
| 2015 FY | -9.28 Billion KRW | -173.53% |
| 2015 Q4 | -9.28 Billion KRW | 79.78% |
| 2015 Q3 | -45.93 Billion KRW | -592.9% |
| 2015 Q2 | 9.32 Billion KRW | -17.45% |
| 2014 Q1 | 9.74 Billion KRW | 58.6% |
| 2014 FY | 12.63 Billion KRW | 105.54% |
| 2014 Q2 | 9.5 Billion KRW | -2.46% |
| 2014 Q4 | 12.63 Billion KRW | 15.97% |
| 2014 Q3 | 10.89 Billion KRW | 14.56% |
| 2013 Q4 | 6.14 Billion KRW | -24.29% |
| 2013 FY | 6.14 Billion KRW | -35.5% |
| 2013 Q1 | 6.88 Billion KRW | -27.78% |
| 2013 Q2 | 5.02 Billion KRW | -26.91% |
| 2013 Q3 | 8.11 Billion KRW | 61.42% |
| 2012 FY | 9.52 Billion KRW | -52.74% |
| 2012 Q4 | 9.52 Billion KRW | 0.0% |
| 2012 Q1 | 19.47 Billion KRW | 0.0% |
| 2011 FY | 20.16 Billion KRW | -54.43% |
| 2011 Q3 | 21.7 Billion KRW | -31.17% |
| 2011 Q1 | 41.3 Billion KRW | -6.64% |
| 2011 Q2 | 31.53 Billion KRW | -23.65% |
| 2010 Q3 | 40.8 Billion KRW | -7.26% |
| 2010 Q1 | 37.04 Billion KRW | 4.08% |
| 2010 Q2 | 44 Billion KRW | 18.77% |
| 2010 FY | 44.24 Billion KRW | 24.31% |
| 2010 Q4 | 44.24 Billion KRW | 8.42% |
| 2009 FY | 35.59 Billion KRW | 24.5% |
| 2009 Q4 | 35.59 Billion KRW | -12.16% |
| 2009 Q3 | 40.52 Billion KRW | 7.59% |
| 2009 Q2 | 37.66 Billion KRW | 16.84% |
| 2009 Q1 | 32.23 Billion KRW | 12.75% |
| 2008 Q2 | 13.23 Billion KRW | 9.16% |
| 2008 Q1 | 12.12 Billion KRW | -14.22% |
| 2008 Q3 | 21.05 Billion KRW | 59.02% |
| 2008 Q4 | 28.58 Billion KRW | 35.8% |
| 2008 FY | 28.58 Billion KRW | 102.21% |
| 2007 Q3 | 14.42 Billion KRW | 6.08% |
| 2007 Q1 | 10.53 Billion KRW | 0.0% |
| 2007 Q2 | 13.59 Billion KRW | 29.11% |
| 2007 FY | 14.13 Billion KRW | 0.0% |
| 2007 Q4 | 14.13 Billion KRW | -1.99% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | -34.786% |
| Yuhan Corporation | -69.18 Billion KRW | 53.124% |
| Yuhan Corporation | -69.18 Billion KRW | 53.124% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 468.45% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 468.45% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 468.45% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 110.433% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 118.535% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 105.67% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 121.009% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 121.009% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 121.009% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -779.912% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 107.67% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 188.041% |
| HANDOK Inc. | 283.45 Billion KRW | 111.442% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 123.848% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 261.576% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 54.855% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 118.972% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 79.711% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 127.942% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 154.348% |
| Boryung Corporation | 187.72 Billion KRW | 117.276% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 241.0% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 127.902% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 142.857% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 142.857% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 107.557% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 120.488% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 27.501% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 139.302% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 1479.308% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 1479.308% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 297.453% |
| CKD Bio Corp. | 143.29 Billion KRW | 122.633% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 109.055% |
| JW Holdings Corporation | 480.68 Billion KRW | 106.747% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 116.14% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 106.262% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 116.722% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 27694.248% |
| JW Lifescience Corporation | 26.09 Billion KRW | 224.305% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 119.706% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 162.4% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 229.168% |